Suppr超能文献

HER2+(人表皮生长因子受体2阳性)乳腺癌小脑转移治疗后软脑膜癌病的治疗:病例报告及文献复习

Treatment of Leptomeningeal Carcinomatosis Following Treatment of Cerebellar Metastasis of HER2+ (Human Epidermal Growth Factor Receptor 2 Positive) Breast Cancer: Case Report and Review of Literature.

作者信息

Smith Parker D, Bhenderu Lokeshwar S, Kommuri Sarayu, Fleener Erin E, Hoover Jason M

机构信息

Molecular and Cellular Medicine, Texas A&M (Agricultural and Mechanical College) Health Science Center, Bryan, USA.

Neurological Surgery, Texas A&M (Agricultural and Mechanical College) Health Science Center, Bryan, USA.

出版信息

Cureus. 2022 Apr 10;14(4):e24008. doi: 10.7759/cureus.24008. eCollection 2022 Apr.

Abstract

Leptomeningeal carcinomatosis (LC) after metastasis of breast cancer is a rare occurrence with potentially devastating complications. Treatment options are limited, and there is a lack of literature on this topic. We report the case of a 38-year-old woman with estrogen/progesterone receptor negative (ER/PR-), human epidermal growth factor receptor 2 positive (HER2+) invasive ductal carcinoma of the left breast who underwent bilateral mastectomies with axillary lymph node dissection and chemotherapy treatment. The patient returned 11 months later with persistent headaches. Imaging and resection found cerebellar metastasis of the breast carcinoma. The brain metastasis was treated with further chemotherapy and stereotactic radiosurgery. Follow-up imaging showed the development of small lesions outside the radiation site. Metabolic studies were performed to determine if the new lesions were due to tumor recurrence or radiation necrosis, but the studies were inconclusive as to the etiology of these lesions. The patient later developed LC that was successfully treated with full resolution of the disease using intrathecal trastuzumab. There are currently no consensuses on treatment guidelines for treating LC. Here, we demonstrate successful treatment of LC from an ER/PR-, HER2+ breast carcinoma with intrathecal trastuzumab.

摘要

乳腺癌转移后发生软脑膜癌病(LC)较为罕见,且可能引发严重并发症。治疗选择有限,关于这一主题的文献也较为匮乏。我们报告了一例38岁女性患者,其左乳腺雌激素/孕激素受体阴性(ER/PR-)、人表皮生长因子受体2阳性(HER2+)浸润性导管癌,接受了双侧乳房切除术及腋窝淋巴结清扫术和化疗。11个月后患者因持续头痛复诊。影像学检查及切除发现乳腺癌小脑转移。脑转移瘤接受了进一步化疗和立体定向放射外科治疗。随访影像学检查显示放疗部位外出现小病灶。进行了代谢研究以确定新病灶是肿瘤复发还是放射性坏死,但这些研究对于这些病灶的病因尚无定论。该患者后来发生了LC,通过鞘内注射曲妥珠单抗成功治愈,疾病完全缓解。目前对于LC的治疗指南尚无共识。在此,我们展示了鞘内注射曲妥珠单抗成功治疗ER/PR-、HER2+乳腺癌所致LC的病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e3d/9090228/89dc4606e690/cureus-0014-00000024008-i01.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验